Genzyme's Wyntek Buy To Accelerate Point-Of-Care Stroke Test R&D
This article was originally published in The Gray Sheet
Executive Summary
Genzyme General's $65 mil. cash acquisition of rapid point-of-care test developer Wyntek Diagnostics will broaden Genzyme's existing rapid test portfolio and accelerate development of a quantitative rapid stroke panel, Genzyme says. Announced May 8, the deal is expected to close by July 1.
You may also be interested in...
PoC Test R&D Complicated By Emergency Consent Provisions – Genzyme Rep
FDA emergency research regulations requiring a therapeutic window to obtain informed consent may slow down development of rapid diagnostics for stroke and heart attack, according to Genzyme VP-Regulatory Affairs Robert Yocher
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.